Provided by Tiger Trade Technology Pte. Ltd.

VanEck Pharmaceutical ETF

109.44
-0.1600-0.15%
Post-market: 109.440.00000.00%19:30 EDT
Volume:128.97K
Turnover:14.12M
Market Cap:1.01B
PE:88.68
High:110.48
Open:110.00
Low:109.17
Close:109.60
52wk High:118.00
52wk Low:85.91
Shares:9.19M
Float Shares:9.19M
Volume Ratio:0.66
T/O Rate:1.40%
Dividend:2.17
Dividend Rate:1.98%
EPS(TTM):1.23
EPS(LYR):0.7765
ROE:--
ROA:--
PB:--
PE(LYR):140.94

Loading ...

Dow Jones Top Company Headlines at 11 PM ET: the 'Deeply Nerdy' Founders Behind Nvidia's $13 Billion Bet on Hugging Face | Musk's ...

Dow Jones
·
Sep 04

AbbVie Closes $10.9B Takeover of Apogee, Its Largest Deal Since 2019, With Earnings Lift Expected From 2032

Stock News
·
Sep 04

Eli Lilly Stock (LLY) Gets a Bullish Note from JPMorgan Chase

TIPRANKS
·
Sep 04

Sector Update: Healthcare Stocks Higher Thursday Afternoon

MT Newswires Live
·
Sep 04

Healthcare Stocks Pick up Steam as Investors Play Offense and Defense

Dow Jones
·
Sep 04

Eisai’s Lenvima Combo Trial in Liver Cancer Ends With Mixed but Market-Relevant Results

TIPRANKS
·
Sep 04

Summit Therapeutics Says it is Beating Merck with Its Cancer Drug

Dow Jones
·
Sep 04

AbbVie's Phase 3 Study of Etentamig in Multiple Myeloma Meets Dual Primary Endpoints

MT Newswires Live
·
Sep 03

AbbVie Says Blood Cancer Drug Met Dual Primary Endpoints in Phase 3 Study

Dow Jones
·
Sep 03

AbbVie announces Phase 3 Cervino study met dual primary endpoints of ORR, PFS

TIPRANKS
·
Sep 03

AbbVie's Blood Cancer Drug Meets Late-Stage Trial Goals

Reuters
·
Sep 03

Abbvie - Phase 3 Cervino Study Met Dual Primary Endpoints; Full Results to be Presented Sept 23-26

THOMSON REUTERS
·
Sep 03

Abbvie - Etentamig Demonstrates Low Rates of Cytokine Release Syndrome and Fatal Infections

THOMSON REUTERS
·
Sep 03

Abbvie - Etentamig Achieves 74% Orr and 60% Risk Reduction in Phase 3 Cervino Trial

THOMSON REUTERS
·
Sep 03

Abbvie Announces Positive Topline Results from the Phase 3 Cervino Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma

THOMSON REUTERS
·
Sep 03

AbbVie Closes $10.9 Billion Acquisition of Apogee Therapeutics

MT Newswires Live
·
Sep 03

Apogee Therapeutics Shares Face NASDAQ Suspension as Company Moves to Delist After AbbVie Merger

Reuters
·
Sep 03

Aspen Sees Mounjaro Africa Sales Above $124 Million in 2027

Reuters
·
Sep 03

Abbvie Completes Acquisition of Apogee Therapeutics

THOMSON REUTERS
·
Sep 03

Abbvie - Reaffirms 2026 Q3 Adj Diluted EPS Guidance $3.84-$3.88

THOMSON REUTERS
·
Sep 03